| Q28392427 | 2009 pandemic H1N1 influenza virus elicits similar clinical course but differential host transcriptional response in mouse, macaque, and swine infection models |
| Q37879971 | A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide |
| Q37857345 | Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque |
| Q37874993 | Antibodies to Chlamydia pneumoniae and clinical course in patients with unstable angina pectoris |
| Q33726287 | Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma |
| Q36852798 | Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies |
| Q39365197 | Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory |
| Q22241306 | Atherosclerosis and infection: is the jury still not in? |
| Q33935003 | Background and current knowledge of Chlamydia pneumoniae and atherosclerosis |
| Q37873100 | Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon. |
| Q37877285 | Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae |
| Q52330706 | Chlamydia and Lipids Engage a Common Signaling Pathway That Promotes Atherogenesis. |
| Q37868385 | Chlamydia pneumoniae accelerates coronary artery disease progression in transgenic hyperlipidemia-genetic hypertension rat model |
| Q37871324 | Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure |
| Q73311061 | Chlamydia pneumoniae and atherosclerosis |
| Q33534714 | Chlamydia pneumoniae and atherosclerosis. |
| Q37877547 | Chlamydia pneumoniae and atherosclerosis: links to the disease process |
| Q37852303 | Chlamydia pneumoniae disturbs cholesterol homeostasis in human THP-1 macrophages via JNK-PPARγ dependent signal transduction pathways |
| Q34008875 | Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells |
| Q33890410 | Chlamydia pneumoniae in atherosclerosis |
| Q24311609 | Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways |
| Q37855399 | Chlamydia pneumoniae infection in patients after kidney transplantation treated with spiramycin. |
| Q37872148 | Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages |
| Q37853903 | Chlamydia pneumoniae infection is associated with elevated body mass index in young men. |
| Q37874834 | Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. |
| Q34009858 | Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro |
| Q35701591 | Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? |
| Q37860795 | Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2. |
| Q37873339 | Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells |
| Q33935060 | Chlamydia, inflammation, and atherogenesis |
| Q33609632 | Chlamydial heat shock proteins and disease pathology: new paradigms for old problems? |
| Q33935055 | Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions |
| Q37851604 | Chlamydophila pneumoniae antibodies may be independently associated with increased BMI and percentage of body fat among women |
| Q37853901 | Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response |
| Q37855911 | Chlamydophila pneumoniae: from its proteomics to arteriosclerosis |
| Q37835017 | Cholesterol uptake in the mouse aorta increases during Chlamydia pneumoniae infection |
| Q33843633 | Chronic infection and coronary artery disease |
| Q79299394 | Chronic infection and coronary artery disease |
| Q33596962 | Chronic infection in the aetiology of atherosclerosis--focus on Chlamydia pneumoniae |
| Q37877605 | De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. |
| Q33916075 | Decreased expression of liver X receptor-α in macrophages infected with Chlamydia pneumoniae in human atherosclerotic arteries in situ. |
| Q37873461 | Detection of Chlamydia pneumoniae antigenin PBMNCs of healthy blood donors |
| Q36014593 | Endotoxin Disrupts Circadian Rhythms in Macrophages via Reactive Oxygen Species |
| Q28255669 | Foamy macrophages and the progression of the human tuberculosis granuloma |
| Q43427569 | Genitourinary chlamydial infection: a reappraisal and hypothesis |
| Q35144239 | Golgi-dependent transport of cholesterol to the Chlamydia trachomatis inclusion. |
| Q33935046 | Growth in vascular cells and cytokine production by Chlamydia pneumoniae |
| Q40079055 | Gut Microbiota and Atherosclerosis |
| Q33762191 | How to design studies to confirm a link between bacterial infection and atherosclerosis |
| Q34557501 | Human infectious diseases and risk of preeclampsia: an updated review of the literature |
| Q36539539 | Identification and characterization of Chlamydia pneumoniae-specific proteins that activate tumor necrosis factor alpha production in RAW 264.7 murine macrophages |
| Q37864777 | Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. |
| Q37877535 | In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells |
| Q35821202 | Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested |
| Q33921219 | Infections and atherosclerosis |
| Q33697959 | Infectious burden and carotid plaque thickness: the northern Manhattan study. |
| Q34316462 | Inflammation, infection and antimicrobial therapy in coronary heart disease--where do we currently stand? |
| Q33833042 | Inhibition of LDL oxidation and oxidized LDL-induced foam cell formation in RAW 264.7 cells show anti-atherogenic properties of a foliar methanol extract of Scoparia dulcis |
| Q36376749 | Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis. |
| Q37851321 | Interleukin-6-174 G/C promoter polymorphism is associated with persistence of Chlamydia pneumoniae antibodies in young men. |
| Q37873102 | Koala biovar of Chlamydia pneumoniae infects human and koala monocytes and induces increased uptake of lipids in vitro |
| Q35709736 | Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. |
| Q38893448 | Macrophage form, function, and phenotype in mycobacterial infection: lessons from tuberculosis and other diseases |
| Q33639053 | Manipulation of Host Cholesterol by Obligate Intracellular Bacteria |
| Q35583908 | Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques |
| Q34065709 | Microorganisms in the aetiology of atherosclerosis. |
| Q42220565 | New insights into the relationship between viral infection and pregnancy complications |
| Q37867718 | Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells |
| Q24633440 | PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1 |
| Q33671913 | Plaque disruption and thrombosis. Potential role of inflammation and infection |
| Q40622718 | Porphyromonas gingivalis induces murine macrophage foam cell formation |
| Q76341995 | Recurrent perivascular inflammation induced by lipopolysaccharide (endotoxin) results in the formation of atheromatous lesions in vivo |
| Q33933810 | Reperfusion injury after focal myocardial ischaemia: polymorphonuclear leukocyte activation and its clinical implications |
| Q37876249 | Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells |
| Q36732330 | Retinoic acid inhibits the infectivity and growth of Chlamydia pneumoniae in epithelial and endothelial cells through different receptors. |
| Q40745416 | Role for periodontal bacteria in cardiovascular diseases |
| Q37869530 | Role of Chlamydia pneumoniae‐infected macrophages in atherosclerosis developments of the carotid artery |
| Q41894655 | Role of MyD88-dependent and MyD88-independent signaling in Porphyromonas gingivalis-elicited macrophage foam cell formation. |
| Q37835915 | Signaling events in pathogen-induced macrophage foam cell formation |
| Q37875919 | T lymphocyte lines isolated from atheromatous plaque contain cells capable of responding to Chlamydia antigens. |
| Q37851226 | The association of body mass index, waist and hip circumference, and waist-hip ratio with Chlamydia pneumoniae IgG antibodies and high-sensitive C-reactive protein at 31 years of age in Northern Finland Birth Cohort 1966. |
| Q34075142 | The association of infection and coronary artery disease: an update |
| Q33843538 | The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae |
| Q59339809 | The physiology of foamy phagocytes in multiple sclerosis |
| Q34396113 | Transcriptomic signature of Leishmania infected mice macrophages: a metabolic point of view |
| Q35662826 | Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota |
| Q34228219 | Uptake and accumulation of oxidized low-density lipoprotein during Mycobacterium tuberculosis infection in guinea pigs |